natgillin/translations-raw huggingface dataset:
Your ability to drive or use a machine may be affected if your blood sugar is low or high. 
Ako je razina šećera u krvi niska ili visoka to može utjecati na sposobnost vožnje ili rukovanja strojem.
Co-administration of 200 mg ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg repaglinide). 
Istodobna primjena 200 mg ketokonazola povećala je AUC i Cmax repaglinida 1,2 puta uz profile koncentracije glukoze u krvi izmijenjene za manje od 8% pri istodobnoj primjeni (pojedinačna doza repaglinida 4 mg).
Repaglinide is almost completely metabolised, and no metabolites with clinically relevant hypoglycaemic effect have been identified. 
Nije identificiran niti jedan metabolit s klinički značajnim hipoglikemijskim učinkom.
Marketing Authorisation Holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia 
Nositelj odobrenja za stavljanje lijeka u promet KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija
Hepatic impairment No clinical studies have been conducted in patients with hepatic insufficiency. 
Oštećenje funkcije jetre Nisu provedena klinička ispitivanja u bolesnika s insuficijencijom jetre.
Enyglid can also be given with metformin, another medicine for diabetes. 
Enyglid se može primjenjivati i s metforminom, jop jednim lijekom za šećernu bolest.
Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide, the concomitant use of deferasirox with repaglinide should be avoided. 
Budući da interakcije nisu bile utvrđene s dozama repaglinida većim od 0,5 mg, istodobnu primjenu deferasiroksa i repaglinida treba izbjegavati.
If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4). 
Ako je primjena ove kombinacije neophodna, potrebno je pažljivo provoditi klinički nadzor i pratiti razinu glukoze u krvi (vidjeti dio 4.4).
• if you take other medicines or suffer from liver or kidney problems (see other sections of 2. 
To se može dogoditi: - ako uzmete previše Enyglida - ako vježbate više nego obično - ako uzimate druge lijekove ili imate problema s jetrom ili bubrezima (vidjeti druge dijelove podnaslova 2.
The AUC (SD) after 2 mg single dose exposure (4 mg in patients with hepatic insufficiency) was 31.4 ng/ml x hr (28.3) in healthy volunteers, 304.9 ng/ml x hr (228.0) in patients with hepatic insufficiency, and 117.9 ng/ml x hr (83.8) in the elderly type 2 diabetic patients. 
Izloženost repaglinidu povećana je u bolesnika s insuficijencijom jetre te u starijih bolesnika sa šećernom bolešću tipa 2. AUC (SD) nakon primjene pojedinačne doze od 2 mg (4 mg u bolesnika s insuficijencijom jetre) bila je 31,4 ng/ml x sati (28,3) u zdravih dobrovoljaca, 304,9 ng/ml x sati (228,0) u bolesnika s insufijencijom jetre, a 117,9 ng/ml x sati (83,8) u starijih bolesnika sa šećernom bolešću tipa 2.
Abnormal hepatic function, increased liver enzymes Isolated cases of increased liver enzymes have been reported during treatment with repaglinide. 
Tijekom liječenja repaglinidom zabilježeni su pojedinačni slučajevi porasta jetrenih enzima.
Since the interaction has not been established with dosages higher than 0.25 mg for repaglinide, the concomitant use of ciclosporin with repaglinide should be avoided. 
Budući da interakcija nije utvrđena pri dozama repaglinida većim od 0,25 mg, istodobnu primjenu ciklosporina i repaglinida treba izbjegavati.
Hypersensitivity reactions of the skin may occur as erythema, itching, rashes and urticaria. 
Na koži se mogu pojaviti reakcije preosjetljivosti poput eritema, svrbeža, osipa i urtikarije.
Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or warfarin at steady state, when administered to healthy volunteers. 
Pri primjeni u zdravih dobrovoljaca, repaglinid nije imao klinički značajan učinak na farmakokinetička svojstva digoksina, teofilina ili varfarina u stanju dinamičke ravnoteže.
In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a 1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose values. 
U ispitivanju interakcija u zdravih dobrovoljaca, istodobna primjena deferasiroksa (30 mg/kg/dan, 4 dana), umjerenog inhibitora CYP2C8 i CYP3A4 i repaglinida (pojedinačne doze od 0,5 mg) rezultirala je povećanjem sistemske izloženosti repaglinidu (AUC) za 2,3 puta (90% CI [2,03-2,63]) u odnosu na kontrolnu skupinu, povećanjem Cmax za 1,6 puta (90% CI [1,42-1,84]) i malim, ali značajnim sniženjem razine glukoze u krvi.
Repaglinide, like other insulin secretagogues, is capable of producing hypoglycaemia. 
Repaglinid, kao i drugi lijekovi koji potiču izlučivanje inzulina, može izazvati hipoglikemiju.
Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets 
Enyglid 0,5 mg tablete Enyglid 1 mg tablete Enyglid 2 mg tablete
Hypoglycaemic coma and hypoglycaemic unconsciousness 
Hipoglikemijska koma i nesvjestica uzrokovana hipoglikemijom
Each tablet contains 0.5 mg repaglinide. 
Svaka tableta sadrži 0,5 mg repaglinida.
• Thyroid products (used to treat low levels of thyroid hormones). 
- Hormone štitnjače (za liječenje niskih razina hormona štitnjače).
Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets Repaglinide 
Enyglid 0,5 mg tablete Enyglid 1 mg tablete Enyglid 2 mg tablete repaglinid
What Enyglid contains 
Kako Enyglid izgleda i sadržaj pakiranja
After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min. 
Nakon petodnevnoga liječenja repaglinidom (2 mg x 3/dan) u bolesnika s jako oštećenom bubrežnom funkcijom (klirens kreatinina: 20-39 ml/min), rezultati su pokazali značajno dvostruko povećanje izloženosti (AUC) i poluvijeka (t1/2) u usporedbi s bolesnicima s normalnom bubrežnom funkcijom.
In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax about 2.5-fold and 1.8-fold respectively. 
U ispitivanju provedenom na zdravim dobrovoljcima, istodobna primjena repaglinida (pojedinačne doze od 0,25 mg) i ciklosporina (ponavljane doze od 100 mg) povećala je AUC repaglinida otprilike 2,5 puta i Cmax otprilike 1,8 puta.
How to store Enyglid 
Kako čuvati Enyglid
The tablets are white, round and biconvex with bevelled edges. 
Tablete su bijele, okrugle i bikonveksne s ukošenim rubovima.
Enyglid 1 mg tablets 
Enyglid 1 mg tablete
• if you have liver problems. 
- Ako imate problema s bubrezima.
The peak plasma level occurs within one hour post administration. 
Maksimalna koncentracija u plazmi izmjerena je unutar jednog sata nakon primjene.
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. 
Istodobna primjena trimetoprima (160 mg dva puta dnevno), umjerenog inhibitora CYP2C8 i repaglinida (pojedinačna doza od 0,25 mg) povećava AUC, Cmax i t1/2 repaglinida (1,6 puta, 1,4 puta odnosno 1,2 puta) bez statistički značajnog učinka na razinu glukoze u krvi.
Patients receiving other oral hypoglycaemic medicinal products Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide. 
Bolesnici mogu izravno prijeći na repaglinid s nekog drugog oralnog antidijabetika.
A number of medicinal products are known to influence repaglinide metabolism, possible interactions should therefore be taken into account by the physician: 
Stoga liječnik mora uzeti u obzir moguće interakcije:
You may get a hypo (short for hypoglycaemia) if your blood sugar gets too low. 
Možete dobiti hipoglikemiju ako je razina šećera u krvi preniska.
Enyglid 2 mg tablets 
Enyglid 2 mg tablete
Enyglid 0.5 mg tablets 
Enyglid 0,5 mg tablete
• if the acid level in your blood is raised (diabetic ketoacidosis). 
- ako imate šećernu bolest tipa 1. - ako u krvi imate povišenu razinu kiseline (dijabetička ketoacidoza).
Enyglid 0.5 mg tablets Each tablet contains 0.5 mg repaglinide. 
Enyglid 0,5 mg tablete Jedna tableta sadrži 0,5 mg repaglinida.
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0-∞) 5.1-fold and continued administration (75 mg daily dose) increased repaglinide exposure (AUC0-∞) 3.9-fold. 
U ispitivanju interakcija u zdravih dobrovoljaca uz istodobnu primjenu klopidogrela (udarna doza od 300 mg), inhibitora CYP2C8, povećala se izloženost repaglinidu (AUC0-∞) 5,1 puta, a nakon kontinuirane primjene (dnevna doza od 75 mg) povećala se izloženost repaglinidu (AUC0-∞) 3,9 puta.
In an interaction study in healthy volunteers, co-administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. 
Istodobna primjena 250 mg klaritromicina, snažnog inhibitora CYP3A4, u ispitivanju interakcija provedenom na zdravim dobrovoljcima neznatno je povećala AUC repaglinida 1,4 puta i Cmax 1,7 puta te povećala srednju vrijednost AUC inzulina u serumu 1,5 puta i maksimalnu koncentraciju 1,6 puta.
Repaglinide should not be used in breast-feeding women. 
Dojilje ne smiju uzimati repaglinid.
Refraction disorders 
Poremećaji refrakcije
Half-life was prolonged from 1.3 hr to 3.7 hr, resulting in possibly enhanced and prolonged blood glucose-lowering effect of repaglinide, and plasma repaglinide concentration at 7 hr was increased 28.6-fold by gemfibrozil. 
Poluvijek je produljen sa 1,3 na 3,7 sati, rezultirajući mogućim pojačanim i produljenim učinkom repaglinida na snižavanje razine glukoze u krvi.
Co-administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC 8.1-fold and Cmax 2.4-fold in healthy volunteers. 
Istodobna primjena gemfibrozila (600 mg dva puta dnevno), inhibitora CYP2C8 i repaglinida (pojedinačne doze od 0,25 mg) u zdravih dobrovoljaca povećava AUC repaglinida 8,1 puta i Cmax 2,4 puta.
Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited. 
CYP3A4 ima manju ulogu, ali relativni doprinos CYP3A4 može biti povećan ako je CYP2C8 inhibiran.
Each tablet contains 2 mg repaglinide. 
Svaka tableta sadrži 2 mg repaglinida.
STATEMENT OF ACTIVE SUBSTANCE 
POPIS POMOĆNIH TVARI
Your body's response to Enyglid may change if you take other medicines, especially these: 
Reakcija tijela na Enyglid može se promijeniti ako uzimate druge lijekove, osobito ove: - Inhibitore monoaminooksidaze (MAOI) (za liječenje depresije).
Each tablet contains 1 mg repaglinide. 
Svaka tableta sadrži 1 mg repaglinida.
• if you take gemfibrozil (a medicine used to lower increased fat levels in the blood). 
- Gemfibrozil (za snižavanje povišenih razina masnoća u krvi).
Abdominal pain, diarrhoea Common Vomiting, constipation 
Rijetko Poremećaji probavnog sustava Bol u abdomenu, proljev Često Povraćanje, konstipacija Vrlo rijetko Mučnina
Please ask your doctor whether you can drive a car if you: 
Upitajte svog liječnika smijete li upravljati vozilom ako: - imate česte hipoglikemije, - imate malo znakova hipoglikemije ili oni izostaju.
You should not take Enyglid if you are breast-feeding. 
Ne smijete uzimati Enyglid ako dojite.
• ACE-inhibitors (used to treat heart conditions). 
- ACE inhibitore (za liječenje bolesti srca).
Enyglid is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. 
S liječenjem se obično započinje kada se samo dijetom, tjelovježbom i smanjenjem tjelesne težine ne može postići zadovoljavajuća regulacija (ili snižavanje) razine šećera u krvi.
Talk to your doctor if any of the above applies to you. 
Ako se bilo što od gore navedenog odnosi na Vas, obratite se svom liječniku.
At such times diabetic control may be lost. 
U tim se slučajevima može poremetiti regulacija šećerne bolesti.
• Hypersensitivity (such as rash, itchy skin, redening of the skin, swelling of the skin) 
Ne poznata (učestalost se ne može procijeniti iz dostupnih podataka): - Preosjetljivost (kao što je osip, svrbež kože, crvenilo kože, oticanje kože) - Mučnina.
OUTER CARTON 
VANJSKO PAKIRANJE
Trials investigating the combination with other insulin secretagogues have not been performed. 
Nisu provedena ispitivanja o kombinaciji repaglinida s drugim lijekovima koji potiču izlučivanje inzulina.
• St.John's wort (herbal medicine). 
- Gospinu travu (biljni lijek).
KRKA Magyarország Kereskedelmi Kft. Tel.: + 361 (0) 355 8490 
Tel.: + 361 (0) 355 8490
The recommended starting dose is 0.5 mg. One to two weeks should elapse between titration steps (as determined by blood glucose response). 
Između svakog koraka titracije doze (na temelju mjerenja razine glukoze u krvi) trebalo bi proći jedan do dva tjedna.
Yellow iron oxide (E172) - only in 1 mg tablets Red iron oxide (E172) - only in 2 mg tablets 
6.1 Popis pomoćnih tvari celuloza, mikrokristalična (E460) kalcijev hidrogenfosfat, bezvodni karmelozanatrij, umrežena povidon K25 glicerol magnezijev stearat meglumin poloksamer željezov oksid, žuti (E172) - samo u tabletama od 1 mg željezov oksid, crveni (E172) - samo u tabletama od 2 mg
E.J. 
C.
• The active substance is repaglinide. 
Što Enyglid sadrži - Djelatna tvar je repaglinid.
The 2 mg tablets are pink, marbled, round, biconvex with bevelled edges and possible darker spots. 
Tablete od 2 mg su ružičaste, mramorirane, okrugle, bikonveksne s ukošenim rubovima i mogu imati tamnije točke.
Enyglid 2 mg tablets 30 tablets: EU/1/09/580/013 60 tablets: EU/1/09/580/014 90 tablets: EU/1/09/580/015 120 tablets: EU/1/09/580/016 180 tablets: EU/1/09/580/021 270 tablets: EU/1/09/580/017 360 tablets: EU/1/09/580/018 
Enyglid 2 mg tablete 30 tableta: EU/1/09/580/013 60 tableta: EU/1/09/580/014 90 tableta: EU/1/09/580/015 120 tableta: EU/1/09/580/016 180 tableta: EU/1/09/580/021 270 tableta: EU/1/09/580/017 360 tableta: EU/1/09/580/018
60 tablets: EU/1/09/580/014 
60 tableta: EU/1/09/580/014
Enyglid 1 mg tablets 30 tablets: EU/1/09/580/007 60 tablets: EU/1/09/580/008 90 tablets: EU/1/09/580/009 120 tablets: EU/1/09/580/010 180 tablets: EU/1/09/580/020 270 tablets: EU/1/09/580/011 360 tablets: EU/1/09/580/012 
Enyglid 1 mg tablete 30 tableta: EU/1/09/580/007 60 tableta: EU/1/09/580/008 90 tableta: EU/1/09/580/009 120 tableta: EU/1/09/580/010 180 tableta: EU/1/09/580/020 270 tableta: EU/1/09/580/011 360 tableta: EU/1/09/580/012
30 tablets: EU/1/09/580/013 
30 tableta: EU/1/09/580/013
Meglumine 
Doziranje
What Enyglid looks like and contents of the pack The 0.5 mg tablets are white, round and biconvex with bevelled edges. 
Tablete od 0,5 mg su bijele, okrugle i bikonveksne s ukošenim rubovima.
90 tablets: EU/1/09/580/015 
90 tableta: EU/1/09/580/015
The 1 mg tablets are pale brown-yellow, round, biconvex with bevelled edges and possible darker spots. 
Tablete od 1 mg su blijedo smeđe-žute boje, okrugle, bikonveksne s ukošenim rubovima i mogu imati tamnije točke.
120 tablets: EU/1/09/580/004 180 tablets: EU/1/09/580/019 270 tablets: EU/1/09/580/005 360 tablets: EU/1/09/580/006 
120 tableta: EU/1/09/580/004 180 tableta: EU/1/09/580/019 270 tableta: EU/1/09/580/005 360 tableta: EU/1/09/580/006
30 tablets: EU/1/09/580/007 
30 tableta: EU/1/09/580/007
120 tablets: EU/1/09/580/016 180 tablets: EU/1/09/580/021 270 tablets: EU/1/09/580/017 360 tablets: EU/1/09/580/018 
120 tableta: EU/1/09/580/016 180 tableta: EU/1/09/580/021 270 tableta: EU/1/09/580/017 360 tableta: EU/1/09/580/018
120 tablets: EU/1/09/580/010 180 tablets: EU/1/09/580/020 270 tablets: EU/1/09/580/011 360 tablets: EU/1/09/580/012 
120 tableta: EU/1/09/580/010 180 tableta: EU/1/09/580/020 270 tableta: EU/1/09/580/011 360 tableta: EU/1/09/580/012
Immune system disorders 
Poremećaji imunološkog sustava Alergijske reakcije*
60 tablets: EU/1/09/580/002 
60 tableta: EU/1/09/580/002
30 tablets: EU/1/09/580/001 
30 tableta: EU/1/09/580/001
60 tablets: EU/1/09/580/008 
60 tableta: EU/1/09/580/008
90 tablets: EU/1/09/580/003 
90 tableta: EU/1/09/580/003
PHARMACEUTICAL FORM 
NAČIN IZDAVANJA LIJEKA
90 tablets: EU/1/09/580/009 
90 tableta: EU/1/09/580/009
If you get any side effects, talk to your doctor or pharmacist. 
Ako primijetite bilo koju nuspojavu potrebno je obavijestiti liječnika ili ljekarnika.
Adjustment of dose and adherence to diet and exercise should be assessed before classifying a patient as a secondary failure. 
Prije klasificiranja stanja kao sekundarno zatajivanje treba procijeniti da li je doza koju bolesnik uzima ispravna i da li se pridržava dijete i tjelovježbe.
Common (may affect up to 1 in 10 people): 
Često (mogu se javiti u do 1 na 10 osoba): - bol u trbuhu - proljev
• Severe liver problems, abnormal liver function such as, increased liver enzymes in your blood. 
Vrlo rijetko (mogu se javiti u do 1 na 10 000 osoba): - povraćanje - zatvor - poremećaji vida - teški problemi s jetrom, poremećaj funkcije jetre kao što je porast jetrenih enzima u krvi.
You should usually receive your infusion once every 3 weeks. 
Obično biste infuziju trebali dobivati jednom svaka 3 tjedna.
24 April 2017 
24. travanj 2017.
The use of gloves is recommended. 
Preporučuje se uporaba rukavica.
The overall response rate was 14.1%. 
Stopa ukupnog odgovora iznosila je 14,1%.
You must contact your doctor immediately if you notice any of the following: 
Morate se odmah javiti svom liječniku ako primijetite bilo što od sljedećeg:
- if you have recently received or are about to receive a vaccine against yellow fever. 
- ako ste nedavno primili ili ćete uskoro primiti cjepivo protiv žute groznice.
Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you. 
Pažljivo pročitajte cijelu uputu prije nego počnete primati ovaj lijek jer sadrži Vama važne podatke.
Mannitol E 421 
Manitol E 421
Be careful when driving a car or using machines. 
Budite oprezni kada upravljate vozilom ili rukujete strojevima.
The infusion will last approximately 10 minutes. 
Infuzija će trajati otprilike 10 minuta.
• Median (m) 
• Medijan (m)
• Stable disease (%) 
• stabilna bolest (%)
ITT population and histology subgroups 
ITT populacija i histološke podskupine
Store below 30°C 
Čuvati na temperaturi ispod 30°C
No dose reductions other than those recommended for all patients are necessary. 
Nisu potrebna druga sniženja doze osim onih preporučenih za sve bolesnike.
*Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%. 
*Definicije pojmova učestalosti: vrlo često - ≥ 10%; često - > 5% i < 10%.
The primary efficacy analysis was based on the ITT population. 
Analiza primarne djelotvornosti temeljila se na ITT populaciji.
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. 
Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku.
In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products. 
Zbog nedostatka ispitivanja kompatibilnosti, ovaj lijek se ne smije miješati s drugim lijekovima.
Pack of 1 vial. 
Pakiranje od 1 bočice.
Your doctor will discuss with you the potential risk of taking pemetrexed during pregnancy. 
Liječnik će s Vama razgovarati o mogućem riziku primjene pemetrekseda u trudnoći.
Treatment may be delayed to allow sufficient time for recovery. 
Ciklus se može odgoditi kako bi se bolesniku omogućilo dovoljno vremena za oporavak.
The risk is increased in subjects who are already immunosuppressed by their underlying disease. 
Rizik je veći u osoba koje su već imunokompromitirane zbog osnovne bolesti.
• Non-inferiority p-value (HR) 
• p-vrijednosti za neinferiornost (HR)
The reporting rates shown are according to CTCAE version 3.0. 
Prikazane stope prijavljivanja u skladu su s CTCAE verzijom 3.0.
Most of these events resolved after pemetrexed withdrawal. 
Većina ovih događaja povukla se nakon prestanka primjene pemetrekseda.
Infection (sepsis) may be severe and could lead to death. 
Infekcija (sepsa) može biti vrlo teška i potencijalno smrtonosna
Contraceptive measures or abstinence are recommended. 
Preporučuje se primjena kontracepcijskih mjera ili apstinencija.
Any diarrhoea requiring hospitalisation (irrespective of grade) or Grade 3 or 4 diarrhoea 
Svaki proljev koji zahtijeva hospitalizaciju (bez obzira na stupanj) ili proljev stupnja 3 ili 4
Survival time (months) 
Vrijeme preživljenja (mjeseci)
If necessary, creatinine clearance should be closely monitored. 
Ako je potrebno, treba pažljivo nadzirati klirens kreatinina.
Gently swirl each vial until the powder is completely dissolved. 
Svaku bočicu nježno vrtite dok se prašak u potpunosti ne otopi.
The infusion of cisplatin will last approximately 2 hours. 
Infuzija cisplatina traje otprilike 2 sata.
Based on the planned date of your infusion of pemetrexed and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. 
Ovisno o planiranom datumu primjene infuzije pemetrekseda i/ili Vašoj bubrežnoj funkciji, liječnik Vam mora reći koje lijekove možete uzimati i kada ih možete uzimati.
• 95% CI for median 
• 95% CI za medijan
• Median 
• Medijan
PFS data were partially confirmed by an independent review (400/1725 patients were randomly selected for review). 
Podaci za PFS djelomično su potvrđeni neovisnom procjenom (400/1725 bolesnika bilo je nasumce odabrano za procjenu).
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. 
Obavijestite svog liječnika ili bolničkog ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove, uključujući lijekove koje ste nabavili bez recepta.
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs. 
Ako niste sigurni, pitajte svog liječnika ili ljekarnika je li koji od Vaših lijekova NSAIL.
Abbreviation: CI = confidence interval. 
Kratice: CI = interval pouzdanosti.
Statistically significant differences in pulmonary function tests were also observed. 
Uočene su i statistički značajne razlike u nalazima testova plućne funkcije.
In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. 
U kliničkim ispitivanjima nije bilo naznaka da bolesnici u dobi od 65 ili više godina imaju veći rizik nuspojava u usporedbi s bolesnicima mlađima od 65 godina.
Caution should be made when these medicinal products are combined with pemetrexed. 
Potreban je oprez kada se ti lijekovi kombiniraju s pemetreksedom.
Female fertility was not investigated. 
Utjecaj na plodnost ženki nije istražena.
Frequency estimate: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from available data). 
Procjena učestalosti: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).